Martina M.D. Flammer Sells 1,384 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,384 shares of Insmed stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total value of $95,108.48. Following the completion of the sale, the insider now owns 100,165 shares of the company’s stock, valued at $6,883,338.80. The trade was a 1.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total value of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The stock was sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Stock Down 0.3 %

NASDAQ INSM opened at $72.51 on Friday. The stock’s 50 day moving average is $71.18 and its 200 day moving average is $72.57. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The stock has a market cap of $12.97 billion, a PE ratio of -13.06 and a beta of 1.12.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the previous year, the company posted ($1.10) earnings per share. The company’s quarterly revenue was up 18.1% compared to the same quarter last year. Research analysts predict that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INSM has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. Bank of America boosted their price target on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Truist Financial restated a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC purchased a new position in Insmed in the 3rd quarter worth approximately $30,000. GAMMA Investing LLC raised its holdings in shares of Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Insmed by 2,348.8% during the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 1,879 shares in the last quarter. Finally, JCIC Asset Management Inc. purchased a new stake in shares of Insmed during the 3rd quarter worth approximately $133,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.